Strategic Partnership Upgrade: Cognizant has signed a five-year agreement with ERIKS to manage all operational IT services, aiming to enhance operational efficiency and allow ERIKS to focus on its most critical IT strategic objectives.
Enhanced Technical Capabilities: This collaboration will accelerate ERIKS' development in emerging technologies like GenAI, not only improving its digital capabilities but also expanding its potential for business growth across Europe and beyond.
Long-term Collaborative Relationship: Since 2017, Cognizant and ERIKS have built a strong partnership, and this new agreement elevates their collaboration to a strategic level, further solidifying Cognizant's position as a trusted partner for ERIKS.
Market Responsiveness: By serving as an adaptable extension of ERIKS' IT department, Cognizant enables effective responses to evolving business needs, supporting ERIKS' competitiveness in a rapidly changing business environment.
CTSH
$83.56+Infinity%1D
Analyst Views on CTSH
Wall Street analysts forecast CTSH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTSH is 85.27 USD with a low forecast of 78.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast CTSH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTSH is 85.27 USD with a low forecast of 78.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
8 Hold
0 Sell
Moderate Buy
Current: 84.050
Low
78.00
Averages
85.27
High
100.00
Current: 84.050
Low
78.00
Averages
85.27
High
100.00
UBS
Neutral
maintain
$78 -> $82
2025-12-08
Reason
UBS
Price Target
$78 -> $82
2025-12-08
maintain
Neutral
Reason
UBS raised the firm's price target on Cognizant to $82 from $78 and keeps a Neutral rating on the shares.
William Blair
Maggie Nolan
Market Perform -> Outperform
upgrade
2025-11-21
Reason
William Blair
Maggie Nolan
Price Target
2025-11-21
upgrade
Market Perform -> Outperform
Reason
William Blair analyst Maggie Nolan upgraded Cognizant to Outperform from Market Perform without a price target after hosting meetings with management. The firm says Cognizant's leading indicators, such as bookings, deal pipeline, and the growth of its financial services and health sciences verticals, indicate "healthier, sustainable" growth for the next 12-18 months. Cognizant has momentum after five consecutive quarters of positive organic constant-currency growth, the analyst tells investors in a research note. Blair believes Cognizant is entering a "new phase of growth and profitability," driven by an accelerated artificial intelligence-focused strategy.
William Blair
Market Perform -> Outperform
upgrade
2025-11-21
Reason
William Blair
Price Target
2025-11-21
upgrade
Market Perform -> Outperform
Reason
William Blair upgraded Cognizant to Outperform from Market Perform.
UBS
Neutral
maintain
$72 -> $78
2025-10-30
Reason
UBS
Price Target
$72 -> $78
2025-10-30
maintain
Neutral
Reason
UBS raised the firm's price target on Cognizant to $78 from $72 and keeps a Neutral rating on the shares. The beat and raise quarter offers certainty amid uncertainty, the analyst tells investors in a research note.
About CTSH
Cognizant Technology Solutions Corporation engineers modern businesses. Its services include artificial intelligence (AI) and other technology services and solutions, consulting, application development, systems integration, quality engineering and assurance, application maintenance, infrastructure and security as well as business process services and automation. Its segments include Health Sciences (HS), Financial Services (FS), Products and Resources (P&R), and Communications, Media and Technology (CMT). HS segment consists of healthcare providers and payers, and life sciences companies. FS segment includes banking, capital markets, payments and insurance companies. P&R segment includes manufacturers, automakers, retailers, consumer goods companies, and travel and hospitality companies, as well as businesses providing logistics, energy and utility services. CMT segment includes global communications, media and entertainment, education, information services and technology companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
